April 15 (Reuters) - Johnson & Johnson JNJ.N:
J&J EXEC SAYS EXPECTS APPROVAL OF CAPLYTA LATER THIS YEAR AS AN ADJUNCTIVE TREATMENT FOR MAJOR DEPRESSIVE DISORDER - CONF CALL
J&J EXEC SAYS IMPLEMENTING A RESTRUCTURING PROGRAM TO SIMPLIFY AND FOCUS THE OPERATIONS OF ITS SURGERY BUSINESS - CONF CALL
J&J EXEC SAYS PLAN TO EXIT CERTAIN NON STRATEGIC PRODUCT LINES GLOBALLY & OPTIMIZE SELECT SITES ACROSS THE NETWORK FOR SURGERY BUSINESS
J&J EXEC SAYS CO EXPECTS SOME MODEST SHORT TERM REVENUE DISRUPTION IN SURGERY BUSINESS OF ABOUT $250 MILLION OVER THE NEXT TWO YEARS
J&J EXEC SAYS RESTRUCTURING PROGRAM FOR SURGERY BUSINESS IS EXPECTED TO BE COMPLETED IN 2027 WITH COST ESTIMATED AT ABOUT $900 MILLION
J&J CEO SAYS "NOT TARIFFS, BUT TAX POLICY" IS THE MOST EFFECTIVE WAY TO BUILD MANUFACTURING CAPACITY IN THE US FOR MEDICAL DEVICES AND PHARMACEUTICALS
J&J CEO SAYS PHARMACEUTICALS "TARIFFS CAN CREATE DISRUPTIONS IN THE SUPPLY CHAIN, LEADING TO SHORTAGES"
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.